Join BenevolentAI’s CFO, Nick Keher, for a panel discussion on whether ‘hot therapeutic areas of investor focus are a help or a hindrance to innovation’.
Join BenevolentAI’s Co-Founder, Ivan Griffin, for a discussion on AI and the future of drug discovery alongside speakers from Charm Therapeutics and Goldman Sachs.
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, presented at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Joanna Shields, CEO BenevolentAI shares her reflection on Responsible AI and innovation following her recent involvement at the GPAI Summit and Paris Peace Forum.